Pathomorphological study of trephinobiopsy specimens from 129 patients with lymphoproliferative and myeloproliferative diseases was carried out over the course of chemotherapy. Combinations of initial and manifest myelofibrosis (loose network of reticulin fibers and extensive network of reticulin and collagen fibers, respectively) predominated at the debut of chronic myeloid leukemia, chronic lymphoid leukemia, and multiple myeloma. Manifest myelofibrosis was detected in patients with chronic myeloid leukemia without hematological response (failure of normalization of hematological values) and in patients with progressing and relapsing multiple myeloma. Combinations of foci of initial and manifest myelofibrosis were most incident in patients with progressing and relapsing chronic lymphoid leukemia. The incidence of myelofibrosis was higher in patients with multiple myeloma and chronic lymphoid leukemia progression and relapses and in patients with chronic myeloid leukemia without hematological response than at the disease debut and in case of response to chemotherapy. The response to chemotherapy in patients with chronic myeloid leukemia and chronic lymphoid leukemia was associated with a decrease in the incidence of myelofibrosis. In patients with multiple myeloma responding to chemotherapy, the incidence of myelofibrosis did not change in comparison with the disease debut.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abdulkadurov KM, Abdullaev AO, Avdeeva LB, Afanas’ev BV, Vinogradova EYu, Vinogradova OYu, Volkova SA, Glonina NN, Gluzhina EV, Golenkov AK, Gusarova GA, Domracheva EV, Dubov SK, Zaklyakova LV, Zaritskii AYu, Ivanova VL, Krinitsyna EE, Kuznetsova SV, Kuz’mina LA, Kutsev SI, Kuchma GB, Lazareva OV, Lomaia EG, Martynkevich IS, Matveeva LF, Morozova EV, Pepelyaeva VM, Rusakov MN, Sudarikov AB, Turkina AG, Fominykh MS, Khoroshko ND, Tsaur GA, Chelusheva EYu, Shuvaev VA, Shukhov OA. Federal Clinical Recommendations for the diagnosis and therapy of chromic myeloid leukemia. Vestn. Gematol. 2013;9(3):4-41. Russian.
Dolgikh TYu, Kachesov IV, Marchenko AA, Domnikova NP. Clinical and pathomorphological examination of myelofibrosis in chronic myeloid leukemia. Sib. Onkol. Zh. 2015;(6):39-45. Russian.
Domnikova NP, Dolgikh TY, D’yachkova YA, Maltseva NA, Kachesov IV, Marchenko AA. Study of clinical and laboratory significance of myelofibrosis in multiple myeloma. Sib. Nauch. Med. Zh. 2014;34(6):76-81. Russian.
Dyachkova YuA, Dolgikh TYu, Domnikova NP. Clinico-pathomorphological study of myelofibrosis in multiple myeloma. Sib. Onkol. Zh. 2014;(3):34-38. Russian.
Clinical Oncohematology. Volkova MA, ed. Moscow, 2007. Russian.
Mendeleeva LP, Votyakova OM, Pokrovskaya OS, Rekhtina IG, Bessmel’tsev SS, Golubeva ME, Darskaya EI, Zagoskina TP, Zinina EE, Kaplanov KD, Konstantinova TS, Kryuchkova IV, Medvedeva NV, Motorin SV, Pospelova TI, Ryzhko VV, Samoilova OS, Urnova ES, Savchenko VG. National clinical guidelines for the diagnosis and treatment of multiple myeloma. Gematol. Transfusiol. 2014;59(S3):2-24. Russian.
Dolgikh TJ, Domnikova NP, Kachesov IV, Marchenko AA. Patent RF No. 2552928. Method of Automated Morphometric Myelofibrosis Diagnostics. Bull. No. 16. Published June 10, 2015.
Russian Clinical Guidelines for the Diagnosis and Treatment of Lymphoproliferative Diseases. Poddubnoi IV, Savchenko VG, eds. Moscow, 2013. Russian.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk. Res. 2013;37(2):214-220.
Ribatti D, Moschetta M, Vacca A. Microenvironment and multiple myeloma spread. Thromb. Res. 2014;133(Suppl. 2):S102-S106.
Tadmor T, Shvidel L, Aviv A, Ruchlemer R, Bairey O, Yuklea M, Herishanu Y, Braester A, Rahimi-Levene N, Vernea F, Ben-Ezra J, Bejar J, Polliack A.; Israeli CLL Study Group. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications. Cancer. 2013;119(10):1853-1859.
Thiele J, Kvasnicka HM, Beelen DW, Flucke U, Spoer C, Paperno S, Leder LD, Schaefer UW. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients. Mod. Pathol. 2001;14(2):129-138.
Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 162, No. 10, pp. 481-485, October, 2016
Rights and permissions
About this article
Cite this article
Dolgikh, T.Y., Domnikova, N.P., Tornuev, Y.V. et al. Incidence of Myelofibrosis in Chronic Myeloid Leukemia, Multiple Myeloma, and Chronic Lymphoid Leukemia during Various Phases of Diseases. Bull Exp Biol Med 162, 483–487 (2017). https://doi.org/10.1007/s10517-017-3645-x
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-017-3645-x